Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
227 USD | +8.84% |
|
-1.73% | -6.81% |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Weaknesses
- The company is in debt and has limited leeway for investment
- With an expected P/E ratio at 32.11 and 28.46 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- With an enterprise value anticipated at 3.91 times the sales for the current fiscal year, the company turns out to be overvalued.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-6.81% | 66.14B | - | ||
-5.50% | 178B | C+ | ||
-5.79% | 98.95B | C | ||
-8.38% | 44.11B | B- | ||
+8.42% | 43.82B | B- | ||
+10.10% | 42.74B | B+ | ||
+10.97% | 28.92B | B | ||
+18.89% | 25.06B | A- | ||
-8.39% | 23.38B | A- | ||
-11.25% | 21.93B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- BDX Stock
- 0R19 Stock
- Ratings Becton, Dickinson and Company